Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.
Haonan Yu, Xiangyuan Bao, Yian Gu...
https://pubmed.ncbi.nlm.nih.gov/40259061Actively Recruiting
Age: 18Years - 80Years
All Genders
Healthy Volunteers
ID06690957
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
Led by Tianjin Medical University · Updated on 2025-02-11
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate the usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) scans for diagnosing primary and metastatic lesions in patients with various somatostatin receptor (SSTR)-related diseases, including tumors. The study focuses on measuring how well these imaging techniques detect and assess SSTR-related conditions by analyzing lesion uptake. Participants receive a single intravenous injection of the 68Ga/18F-TATE/JR11/LM3 tracer and then undergo PET/CT imaging within a specified timeframe. The study measures uptake values using the maximum standard uptake value (SUVmax) and calculates diagnostic performance indicators such as sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. During the study, patients undergo the PET/CT imaging procedure after tracer injection, and researchers evaluate the standardized uptake value (SUV) within 30 days. Diagnostic efficacy is also assessed in this period. Participants may be healthy volunteers or patients with suspected or known malignant tumors. The study monitors results to understand how well the imaging technique works for detecting disease.
CONDITIONS
Brief Title
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
Who Can Participate
Age: 18Years - 80Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology
- Patients scheduled for somatostatin receptor PET/CT scan
- Patients able to provide informed consent or have a legal representative who can consent
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3 and undergo PET/CT imaging for assessment of somatostatin receptor-related disease.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 30 days
Participants are monitored for diagnostic outcomes and safety following the PET/CT imaging.
Follow-up assessments as needed
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Loading map...
Research Team
H
Haonan Yu, MD
S
Shaobo Yao, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here